“Body Contouring Devices and Procedures Market Report is set to have rapid growth due to the factors, such as quick adoption of technologically advanced products, high domestic income, and rise in demand for noninvasive procedures at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report

04 September 2019
Pharma

Visiongain has launched a new pharma report Body Contouring Devices and Procedures Market Forecast 2019-2029: By Device Type, By Procedure Type (Cellulite Treatment, Liposuction), By End Use, And Segment Forecasts

One of the major reason for increasing demand for body contouring devices and procedures is rising cases of obesity across the globe due to unhealthy lifestyle. The increased life expectancy resulting from the improved safety and efficacy of body contouring devices, besides their ease of use, cost-effective, and less painful has also resulted in the growth of the market. Moreover, initiatives, such as M&A and partnerships, undertaken by major companies for product research and distribution are also fuelling the market growth. The technological development in this segment will fuel its growth.

The market is divided into segments of non-invasive and minimally invasive which holds the major share of the market. This segment also witness massive R&D by the key players which has enhanced safety, short downtimes, and cost-effectiveness of these devices and the procedures.

The clinics and spa centres are the major players in this segment owing to technologically advanced devices and reduced risks of hospital-acquired infections.

Leading companies featured in the report include: Cynosure, Inc., Alma Lasers, Alleragan, Syneron Medical Ltd., Bausch Health Companies, Inc., Lumenis, Merz Pharma, Meridian, InMode Aesthetic Solutions, El.En. S.p.A. (Asclepion Laser Technologies GmbH).

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever